SCHEMBL16058685

SCHEMBL16058685

Cc1c(-c2ccc(Cc3ccccc3)cc2)ccnc1OC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ EPHX1 P07099 1/20 0.37
▸ LTA4H P09960 4/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ ALK Q9UM73 2/20 0.36
▸ KIT P10721 1/20 0.36
▸ GPR52 Q9Y2T5 1/20 0.36
▸ BRS3 P32247 2/20 0.36
▸ PLA2G10 O15496 1/20 0.36
▸ PLA2G2A P14555 1/20 0.36
▸ PTPN1 P18031 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16058375 0.89 PLA2G2A (0.41) GPR52PLA2G10PLA2G2A
SCHEMBL14975894 0.88 PORCN (0.40) MEN1KMT2ARAB9AEPHX1ALDH1A1
SCHEMBL16057947 0.86 SLC22A12 (0.39) MEN1KMT2ARAB9AALDH1A1
SCHEMBL16058150 0.84 PDE10A (0.40) KMT2ARAB9AALDH1A1HPGDL3MBTL1
SCHEMBL16056981 0.84 SLC6A7 (0.41) RAB9AEPHX1ALDH1A1CYP1A2
SCHEMBL16057040 0.83 RAB9A (0.44) LMNAMEN1KMT2ARAB9AALDH1A1
SCHEMBL16057011 0.82 FFAR4 (0.43) LMNALTA4HBRS3PLA2G10PLA2G2A
SCHEMBL16057293 0.82 MAPK1 (0.57) LMNARAB9AHPGDCYP2C9
SCHEMBL16057060 0.82 RARB (0.46) LMNAMEN1KMT2AALDH1A1HPGD
SCHEMBL16057423 0.82 CCNC (0.39) MEN1KMT2AEPHX1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 LMNA 1670/4885MEN1 1885/4885KMT2A 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback